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patients with HDL-c <1mmol/L, treatment with statin plus add-
on Niaspan® was compared to statin monotherapy. Niaspan®
treatment effects were taken from several clinical trials as sum-
marized in the European SPC. The second model (Markov) sim-
ulated the development of coronary heart disease events based
on the Framingham risk formulae. Direct medical costs were
accounted from a third-party payer perspective in the UK and
expressed in pounds sterling (£). Annual discount rates of 3.5%
were applied to clinical and cost outcomes. RESULTS: Niaspan®
was associated with improvements in mean discounted life
expectancy in diabetic (0.32 years) and non-diabetic cohorts
(0.29 years) compared to statin monotherapy. Similarly,
improvements in quality-adjusted life expectancy of (diabetic)
0.26 and (non-diabetic) 0.23 quality-adjusted life years (QALYs)
were projected. Niaspan® was associated with increases in mean
lifetime costs of £4492 (diabetic) and £4891 (non-diabetic)
versus statin alone. This led to incremental cost-effectiveness
ratios of £17,296 per QALY gained in the diabetic cohort and
£21,150 in the non-diabetic cohort. CONCLUSIONS: Addition
of Niaspan® to statin treatment was cost-effective by generally
accepted standards compared to statin monotherapy in patients
with persistently low HDL-c in the UK. In patients with Type-2
diabetes and an associated high risk of CHD events, add-on
therapy with Niaspan® represented better value for money than
in non-diabetic patients.
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OBJECTIVES: To project the long-term clinical and cost out-
comes associated with long-acting insulin analog treatment in
patients with type-1 diabetes in an Austrian setting. METHODS:
We used a published, validated and peer-reviewed computer sim-
ulation model of diabetes to project short-term clinical ﬁndings
to evaluate long-term outcomes including quality-adjusted life
expectancy, complication rates and direct medical costs. Clinical
data have been derived from the PREDICTIVE study, an ongoing
global post-marketing safety study, for a sub-group of patients
with type-1 diabetes receiving long-acting insulin glargine (IGlar)
in a basal/bolus treatment regimen at baseline and switched to
long-acting insulin detemir (IDet). After 12 weeks of follow up,
IDet-based basal/bolus treatment was associated with improve-
ments in HbA1c (0.25%-points lower), reduced risk of hypo-
glycemic events (by 55%), and decreased body weight (0.27kg)
compared to IGlar-based treatment. Probabilities of complica-
tions and HbA1c-dependent adjustments were derived from the
DCCT, Framingham, and WESDR studies (amongst others).
Costs of treating complications were retrieved from published
sources. Total direct costs (complications + treatment costs) were
projected over patient lifetimes. Costs and outcomes were dis-
counted at 3.5% per annum. RESULTS: Improved glycemic
control, decreased hypoglycemic events and BMI with IDet-
based basal/bolus therapy led to fewer diabetes-related compli-
cations and an increase in quality-adjusted life expectancy of
0.13 quality-adjusted life years (QALYs). IDet-based therapy was
associated with slightly higher lifetime direct costs (€394 per
patient) which led to an incremental cost-effectiveness ratio
(ICER) of €3031 per QALY gained. CONCLUSIONS: Short-
term clinical beneﬁts associated with IDet-based basal/bolus
therapy were projected to lead to improvements in quality-
adjusted life expectancy and fewer diabetes related complications
than IGlar-based regimens. Incremental cost-effectiveness analy-
sis indicated that, over patient lifetimes, IDet-based combina-
tions would represent good value for money versus IGlar-based
therapy in the Austrian setting.
PDB20
BIPHASIC INSULIN ASPART 30 VERSUS ORAL
HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2
DIABETES: LONG-TERM PROJECTION OF CLINICAL AND
COST OUTCOMES IN SWEDEN
Palmer AJ1, Lammert M2,Valentine WJ1, Ray JA1, Brandt AS3, Roze S1
1CORE—Center for Outcomes Research, Binningen, Basel,
Switzerland; 2Novo Nordisk, Bagsvaerd, Denmark; 3Novo Nordisk
Scandinavia AB, Malmö, Sweden
OBJECTIVES: To project long-term clinical and cost outcomes
associated with biphasic insulin aspart 30 (BIAsp 30) and oral
hypoglycemic agents (OHAs) in a Swedish setting based on the
ﬁndings of a randomized clinical trial. METHODS: A published,
validated and peer-reviewed model of diabetes was used to sim-
ulate the progression of diabetes-related complications based on
clinical trial data which showed that switching to BIAsp 30 sig-
niﬁcantly reduced HbA1c compared to continuation of OHAs in
insulin-naïve patients with Type-2 diabetes over 16 weeks (dif-
ference in HbA1c reduction 0.648%; p < 0.001). Direct medical
costs were accounted from a third party payer perspective in
Sweden and expressed in 2004 Swedish Kroner (SEK). Costs and
clinical beneﬁts were discounted at 3% annually and sensitivity
analyses were performed on treatment effect, time horizon and
discount rates. RESULTS: BIAsp 30 was projected to extend 
life expectancy (mean [standard deviation]) by 0.47 [0.22] com-
pared to OHAs (11.38 vs. 10.90 years). Quality-adjusted life
expectancy was improved with BIAsp 30 by 0.42 [0.15] quality-
adjusted life years (QALYs) versus OHAs (7.94 vs. 7.52 QALYs).
BIAsp 30 was associated with a lower cumulative incidence of
diabetes-related complications, particularly retinopathy and
nephropathy. Mean direct lifetime costs were higher in the BIAsp
30 group (SEK 286,467 [11,745]) than in patients receiving
OHAs (SEK 272,752 [12,885]), a difference of SEK 13,716
[17,030], leading to an incremental cost-effectiveness ratio of
SEK 32,736 per QALY gained. Sensitivity analysis showed that
these ﬁndings were robust under variation in a range of assump-
tions. CONCLUSIONS: Switching to BIAsp 30 was projected to
reduce the incidence of diabetes-related complications, and
improve life expectancy and quality-adjusted life expectancy,
compared to continuation of OHAs in Type-2 diabetes patients.
Switching to BIAsp 30 was projected to represent good value for
money by internationally accepted standards in the Swedish
setting.
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OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with an increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir + insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced the risk of
hypoglycemic events (by 21%), and decreased body mass index
